Drugs / Myeloma Immunoglobulin Idiotype Vaccine-KLH
Myeloma Immunoglobulin Idiotype Vaccine-KLH
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00001561 | Nov 1996 → Sep 2005 | graft versus host disease, plasma cell myeloma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Myeloma Immunoglobulin Idiotype Vaccine-KLH | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00001561 ↗ |
| Known as | NSC-678327 | “PP-KLH Myeloma immunoglobulin plasma paraprotein vaccine, NSC-678327, with keyhole limpet hemocyanin” NCT00001561 ↗ |
| Known as | PP-KLH | “PP-KLH (individual myeloma immunoglobulin plasma paraprotein vaccine prepared from recipient's plasma paraprotein and conjugated with KLH)” NCT00001561 ↗ |
| Modality | Vaccine | “Vaccine Therapy with Immunoadjuvant” NCT00001561 ↗ |
| Route | Subcutaneous | “Id-KLH (0.5 mg) is administered s.c.” NCT00001561 ↗ |